Ishihara, JunIshihara, AkoPotin, LambertHosseinchi, PeymanFukunaga, KazutoDamo, MartinaGajewski, Thomas F.Swartz, Melody A.Hubbell, Jeffrey A.2018-12-132018-12-132018-12-132018-11-0110.1158/1535-7163.MCT-18-0091https://infoscience.epfl.ch/handle/20.500.14299/152553WOS:000448888000012CD40 is an immune costimulatory receptor expressed by antigen-presenting cells. Agonistic anti-CD40 antibodies have demonstrated considerable antitumor effects yet can also elicit serious treatment-related adverse events, such as liver toxicity, including in man. We engineered a variant that binds extracellular matrix through a super-affinity peptide derived from placenta growth factor-2 (PIGF-2(123-144)) to enhance anti-CD40's effects when administered locally. Peritumoral injection of PIGF-2(123-144)-anti-CD40 antibody showed prolonged tissue retention at the injection site and substantially decreased systemic exposure, resulting in decreased liver toxicity. In four mouse tumor models, PICF-2(123-144)-anti-CD40 antibody demonstrated enhanced antitumor efficacy compared with its unmodified form and correlated with activated dendritic cells, B cells, and 'T' cells in the tumor and in the tumor-draining lymph node. Moreover, in a genetically engineered Braf(V600E) beta Cat(STA )melanoma model that does not respond to checkpoint inhibitors, PIGF-2(123-144)-anti-CD40 antibody treatment enhanced T-cell infiltration into the tumors and slowed tumor growth. Together, these results demonstrate the marked therapeutic advantages of engineering matrix-binding domains onto agonistic anti-CD40 antibody as a therapeutic given by tumori-regional injection for cancer immunotherapy. (C) 2018 AACR.OncologyOncologyimmune checkpoint blockadecd103(+) dendritic cellscancer-therapycd40 ligationmonoclonal-antibodypd-l1 expressionin-vivophase-iimmunotherapytumorstext::journal::journal article::research article